Usage Examples
- The granulation Design Space covers water addition of 3 to 7 percent and inlet air temperature of 50 to 65 C, with dissolution inside specification across the whole region.
- Raising spray rate to 85 g/min puts that batch outside the approved Design Space, so it becomes a post approval change.
- Those are three proven acceptable ranges from univariate runs, not a Design Space. We never varied them together.
What is Design Space?
Design Space is the regulator-approved multivariate region of input material attributes and process parameters demonstrated to assure quality, inside which a manufacturer can move without filing a post-approval change.
Design Space exists to buy manufacturing flexibility with development evidence, and it is optional. ICH Q8(R2) ties the trade together: the degree of regulatory flexibility is predicated on the level of relevant scientific knowledge provided. Without a design space, moving a registered process parameter is a post approval change. With one, movement inside the approved region is not considered a change.
Design Space covers the input variables and process parameters an applicant chooses to include, expressed as ranges, a time dependent function, or a multivariate model, for one unit operation or the whole process, for drug substance and drug product alike. Design Space does not cover parameters left unvaried in development, does not require an edge of failure, and does not emerge from stacking univariate proven acceptable ranges.
Design Space is applied through the dossier and the change control system together. Design Space sits in P.3.3 for a drug product and 3.2.S.2.2 for a drug substance, is assessed by the reviewer, and is approved with the application. ICH Q11 is explicit that movements within the design space still go through internal change management; they simply do not require regional regulatory approval.
Not to be confused with
- Proven Acceptable Range (PAR)
- a PAR is characterised univariately, holding every other parameter constant. ICH Q8(R2) states outright that a combination of proven acceptable ranges does not constitute a design space, because PARs carry no evidence about what happens when two parameters move together.
- Normal Operating Range (NOR)
- the NOR is the narrower band a plant actually runs to, and it sits inside the Design Space. ICH Q8(R2) does not define NOR at all, which is the point: the NOR is an internal target, so drifting off it while staying inside the Design Space is a deviation to investigate, not a filing.
- Established Conditions (ICH Q12)
- ECs are the legally binding elements of a dossier that necessitate a submission if changed, defined in ICH Q12, adopted 20 November 2019. A Design Space is one way to justify wider EC ranges and lower reporting categories; it is not the same object, and Q12 says identifying ECs is not mandatory unless a regional requirement makes it so.
- Edge of failure
- the edge of failure is the point beyond which the relevant quality attributes cannot be met. Q8(R2) is explicit that determining it is not an essential part of establishing a design space, and ICH Q11 notes that operating outside the studied ranges does not necessarily produce unacceptable quality, only that quality there is unknown.
There is no single design space checklist. These are the obligations that attach once you propose one.
What you must do
- 1Describe in the application which process parameters and material attributes were considered for the design space, which were included, their effect on product quality, and the rationale for inclusionICH Q8(R2) Annex 2.4.1
- 2Highlight the process parameters and material attributes that were not varied through developmentICH Q8(R2) Annex 2.4.1
- 3Demonstrate the region multivariately rather than submitting a combination of proven acceptable ranges, which does not constitute a design spaceICH Q8(R2) Annex 2.4.5
- 4Locate the drug product design space in P.3.3, with additional detail in P.3.4 and the supporting development studies summarised in P.2.1, P.2.2 and P.2.3; ICH Q11 section 8.3 places the drug substance equivalent in 3.2.S.2.2 and 3.2.S.2.4ICH Q8(R2) Annex 3.2
- 5Propose the design space for regulatory assessment and approval; it confers no flexibility until the application is approvedICH Q8(R2) Part I Section 3 (Glossary)
- 6Route every movement within the approved design space through internal change management under the quality system, even though it needs no regional regulatory approvalICH Q11 Section 9 (Lifecycle Management)
Common mistakes
Stacking one-factor-at-a-time ranges and calling it a Design Space
ICH Q8(R2) settles this in one sentence: a combination of proven acceptable ranges does not constitute a design space. Univariate runs hold every other parameter fixed, so they say nothing about the corners where two parameters move together, and the corners are where a region fails. That is a deficiency, not a design space.
Filing a pilot-scale Design Space with no scale-up justification
Q8(R2) allows a design space to be developed at any scale but requires the applicant to justify its relevance to the proposed production scale, discuss scale-up risk, and use scale-independent parameters if the space is meant to span scales. A shear-sensitive mixing step described by agitation rate instead of shear rate does not transfer, and the flexibility disappears at commercial scale.
Treating movement inside the Design Space as needing no paperwork at all
ICH Q11 is explicit that movements within the design space are still subject to internal change management under the quality system. What they avoid is regional regulatory approval, not change control. Teams that skip the internal record cannot show an inspector why a batch ran where it ran, and the Q8(R2) benefit turns into a GMP finding.
When This Matters
- The granulation Design Space covers water addition of 3 to 7 percent and inlet air temperature of 50 to 65 C, with dissolution inside specification across the whole region.
- Raising spray rate to 85 g/min puts that batch outside the approved Design Space, so it becomes a post approval change.
- Those are three proven acceptable ranges from univariate runs, not a Design Space. We never varied them together.
Frequently Asked Questions
No. ICH Q8(R2) states that working within the design space is not considered as a change, so it does not trigger a regulatory post approval change process. It is still a change under your quality system: ICH Q11 confirms movements within the design space remain subject to internal change management, they just need no regional regulatory approval.
Related Use Cases
- Pharma Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
- Biotech Use Cases
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
- CMC Workflows
Track ICH quality guidelines automatically and get alerts when changes impact your products
- Quality/QA Workflows
Track GxP regulation changes and enforcement trends
